LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Glutathione peroxidase 3 (GPx-3), also known as plasma glutathione peroxidase (GPx-P) or extracellular glutathione peroxidase is an enzyme that in humans is encoded by the GPX3 gene. GPx-3 belongs to the glutathione peroxidase family, which functions in the detoxification of hydrogen peroxide. It contains a selenocysteine (Sec) residue at its active site. The selenocysteine is encoded by the UGA codon, which normally signals translation termination. The 3' UTR of Sec-containing genes have a common stem-loop structure, the sec insertion sequence (SECIS), which is necessary for the recognition of UGA as a Sec codon rather than as a stop signal.
Before the second half of the nineteenth century, the remarkable potency and specificity of the actions of drugs such as morphine, quinine, and digitalis were explained vaguely and with reference to extraordinary chemical powers and affinities to certain organs or tissues. The first pharmacology department was set up by Rudolf Buchheim in 1847, at the University of Tartu, in recognition of the need to understand how therapeutic drugs and poisons produced their effects. Subsequently, the first pharmacology department in England was set up in 1905 at University College London. Pharmacology developed in the 19th century as a biomedical science that applied the principles of scientific experimentation to therapeutic contexts. The advancement of research techniques propelled pharmacological research and understanding. The development of the organ bath preparation, where tissue samples are connected to recording devices, such as a myograph, and physiological responses are recorded after drug application, allowed analysis of drugs' effects on tissues. The development of the ligand binding assay in 1945 allowed quantification of the binding affinity of drugs at chemical targets. Modern pharmacologists use techniques from genetics, molecular biology, biochemistry, and other advanced tools to transform information about molecular mechanisms and targets into therapies directed against disease, defects or pathogens, and create methods for preventive care, diagnostics, and ultimately personalized medicine.
== X == XAES – X-ray induced Auger electron spectroscopy XANES – XANES, synonymous with NEXAFS (near edge X-ray absorption fine structure) XAS – X-ray absorption spectroscopy X-CTR – X-ray crystal truncation rod scattering X-ray crystallography XDS – X-ray diffuse scattering XES – X-ray emission spectroscopy XPEEM – X-ray photoelectron emission microscopy XPS – X-ray photoelectron spectroscopy XRD – X-ray diffraction XRES – X-ray resonant exchange scattering XRF – X-ray fluorescence analysis XRR – X-ray reflectivity XRS – X-ray Raman scattering XRT – X-ray transmission XSW – X-ray standing wave technique
=== Primary packaging === Primary packaging is directly in contact with the food products, creating the ideal headspace for them, while providing protection from external alteration. Additionally, primary packaging, also known as retail packaging or consumer units, is responsible for the marketing aspects of food packaging. Typically, the packaging materials used in the primary level include cardboard cartons, plastic trays, glass bottles and multi-layered structures (Tetra Pak).
While the production of alcohol is the most noteworthy by-product of yeast metabolism from a winemaking perspective, there are a number of other products that yeast produce that can be also influence the resulting wine. This includes glycerol which is produced when an intermediate of the glycolysis cycle (dihydroxyacetone) is reduced to "recharge" the NADH enzyme needed to continue other metabolic activities. This is usually produced early in the fermentation process before the mechanisms to reduce acetaldehyde into ethanol to recharge NADH becomes the cell's primary means of maintaining redox balance. As glycerol contributes increased body and a slightly sweet taste without increasing the alcohol level of the wine, some winemakers try to intentionally favor conditions that would promote glycerol production in wine. This includes selecting yeast strains that favor glycerol production (or allowing some wild yeast like Kloeckera and Metschnikowia to ferment), increased oxygen exposure and aeration as well as fermenting at higher temperatures. Glycerol production is also encouraged if most available acetaldehyde is made unavailable by binding with bisulfite molecules in the wine, but it would take a substantial amount of sulfur dioxide addition (far beyond legal limits) to prolong glycerol production beyond just these very nascent stages of fermentation. Other by-products of yeast include:
Sources: en.wikipedia.org
Сорокин) "Rugby" (Регби) in English translation of Great Soviet Encyclopedia (Progress Publishers, Moscow, 1978) Starmer-Smith, Nigel (ed) Rugby - A Way of Life, An Illustrated History of Rugby (Lennard Books, 1986 ISBN 0-7126-2662-X) Thau, Chris Soviet Rugby in Starmer-Smith, Nigel & Robertson, Ian (eds) The Whitbread Rugby World '89 (Lennard Books, 1988 ISBN 1-85291-038-0) Thau, Chris Soviet Students in Starmer-Smith, Nigel & Robertson, Ian (eds) The Whitbread Rugby World '90 (Lennard Books, 1989 ISBN ) The Ultimate Encyclopaedia of Rugby, (Carlton Books, 1997 ISBN 1-85868-076-X) Dancing On Our Bones: New Zealand, South Africa, Rugby and Racism by Trevor Richards (Bridget Williams Books, 1999). The author was one of a small group of people who founded Halt All Racist Tours (HART) in Auckland in 1969 and worked for the organisation for many years, serving as chair (1969–1980) and international secretary (1980–1985).
Following the release and favorable reviews of Last Days Here, Liebling and Pentagram experienced a significant resurgence in popularity. The documentary won multiple awards, including the Grand Jury Prize at the Independent Film Festival of Boston and Best Music Documentary at the International Documentary Film Festival Amsterdam. This renewed attention revitalized Pentagram's career, leading to international tours. Releasing a new album around the same time the documentary was published accelerated the band's resurgence. Liebling, alongside longtime collaborator Victor Griffin, returned to the studio for Last Rites, which was released in April 2011. This marked Griffin's first studio work with Pentagram in over 15 years. At the time, Liebling noted that he had written the music and lyrics for about half of the band's earlier albums, "while 30–40% were collaborations with musicians, typically guitar players". Regarding his songwriting approach for the "Last Rites", he said: "I just write the lyrics nowadays. I ran out of music. I wrote 450 songs in 30 years." In 2011, Metal Blade Records announced Pentagram's return to live performances, which included an appearance at South by Southwest and a European tour that began at the Roadburn Festival in the Netherlands. Liebling embarked on extensive touring across North America and Europe with Pentagram in the following years. However, the band continued to experience frequent lineup changes. Pentagram maintained its momentum with the release of the album Curious Volume on August 21, 2015.
Bukele and a number of his government officials have attacked journalists and news outlets in speeches and on social media. He has dismissed critics of his government as spreading "fake news" and accused them of being "mercenaries". Bukele has also stated that journalism was once a "noble career that sought the truth" ("carrera noble que buscaba la verdad") that had supposedly become propaganda. Journalists have been harassed and threatened online by Bukele's supporters. The El Salvador Journalists Association (APES) estimated that by November 2022, at least a dozen journalists had fled El Salvador since Bukele took office citing fears for their safety. APES has also stated that journalists have experienced threats, harassment, doxxing, intimidation, surveillance, and criminal prosecution during Bukele's presidency. According to political scientists, El Salvador has experienced democratic backsliding under Bukele as he has dismantled democratic institutions, curtailed political and civil liberties, and attacked independent media and the political opposition. Journalists, politicians, and political analysts have described Bukele as an autocrat, an authoritarian, a strongman, a caudillo, and a "millennial dictator". He has ironically referred to himself in his Twitter profile as the "Dictator of El Salvador", "the coolest dictator in the world" (although news outlets often render this as the "world's coolest dictator"), the "Emperor of El Salvador", the "CEO of El Salvador", and the "Philosopher King".
Hydroxyprogesterone heptanoate (OHPH), also known as hydroxyprogesterone enanthate (OHPE) and sold under the brand names H.O.P., Lutogil A.P., and Lutogyl A.P. among others, is a progestin medication used for progestogenic indications. It has been formulated both alone and in together with estrogens, androgens/anabolic steroids, and other progestogens in several combination preparations (brand names Tocogestan, Trioestrine Retard, and Triormon Depositum). OHPH is given by injection into muscle at regular intervals. OHPH is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It appears to have similar pharmacology to that of the closely related medication hydroxyprogesterone caproate (OHPC). OHPH was first described by 1954 and was introduced for medical use by 1957. It has been used clinically in France and Monaco in the past but is no longer marketed.
== Beryllium-7 == Beryllium-7 is an isotope with a half-life of 53.22 days that is generated naturally as a cosmogenic nuclide. It is also a nuisance byproduct in nuclear reactors and accelerators. The rate at which the short-lived 7Be is transferred from the air to the ground is controlled in part by the weather. 7Be decay in the Sun (the half-life in stars can be greatly different from the normal as it is a free rather than a bound electron that is captured) is one of the sources of solar neutrinos, and the first type ever detected using the Homestake experiment. Presence of 7Be in sediments is often used to establish that they are fresh, i.e. less than about 3–4 months in age, or about two half-lives of 7Be.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.